v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities    
Net income (loss) $ (58,958) $ 241,198
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 1,743 2,062
Stock-based compensation expense 4,968 10,793
Loss on debt extinguishment   10,286
(Gain) loss on Sale Transactions, net (Note 6) 699 (339,102)
Change in fair value of derivatives   12,608
Other non-cash adjustments, net (12,030) 2,490
Changes in operating assets and liabilities:    
Trade receivables, net 3,940 106,161
Inventory (10,875) (18,474)
Prepaids and other current and non-current assets 4,568 (473)
Accounts payable 4,253 833
Accrued rebates, fees and reserves (2,365) (68,053)
TSA related operating assets and liabilities, net (42,174) (10,547)
Accrued compensation (5,299) (7,329)
Accrued and other current and non-current liabilities (8,446) (14,911)
Net cash used in operating activities (119,976) (72,458)
Investing activities    
Purchases of investments in marketable securities (20,285) (20,726)
Proceeds from maturities of investments in marketable securities 81,671  
Net cash received related to the Sale Transactions (Note 6)   478,681
Milestone payment to Junshi Biosciences   (12,500)
Other investing activities, net (1,100) (303)
Net cash provided by investing activities 60,286 445,152
Financing activities    
Proceeds from issuance of common stock under Public Offering, net of issuance costs 53,650  
Partial repayment of Revenue Purchase and Sale Agreement   (47,652)
Proceeds from purchases under the employee stock purchase plan 202 188
Taxes paid related to net share settlement (112) (280)
Repayment and redemption of 2026 Convertible Notes, including transaction costs (121) (233,185)
Other financing activities, net 115 (859)
Net cash provided by (used in) financing activities 53,734 (281,788)
Net increase (decrease) in cash, cash equivalents and restricted cash (5,956) 90,906
Cash, cash equivalents and restricted cash at beginning of period 89,119 126,250
Cash, cash equivalents and restricted cash at end of period $ 83,163 $ 217,156